Table 1.
Clinical characteristics of the MYH7 p. (Asn1918Lys) mutation carriers
| Probands | Family members | |
|---|---|---|
| Clinical diagnosis | (15) | (65) |
| – CMP | 15 (100%) | 31 (47.7%) |
| – CHD | 1 (6.7%) | 6 (9.2%) |
| Clinical measures | (14) | (27) |
| – LVEF | ||
| ∙ <60% | 5 (35.7%) | 17 (63.0%) |
| ∙ <40% | 8 (57.1%) | 5 (18.5%) |
| – Arrhythmia/conduction | ||
| ∙ (P)AF | 0 (0%) | 2 (7.4%) |
| ∙ Total AV block | 0 (0%) | 1 (3.7%) |
| ∙ VT/VF | 1 (7.1%) | 0 (0%) |
| Outcome measures | (15) | (65) |
| – ICD implantation | 6 (40%) | 3 (9.6%)a |
| – Heart transplantation | 0 (0%) | 1 (3.2%) |
| – Death | 0 (0%) | 1 (3.2%) |
n number of carriers with available clinical data, CMP cardiomyopathy, CHD congenital heart disease, LVEF left ventricular ejection fraction, (P)AF (paroxysmal) atrial fibrillation, AV atrioventricular, VT/VF ventricular tachycardia/ventricular fibrillation, ICD implantable cardioverter defibrillator
aCarrier with DDD-R pacemaker excluded